BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Amgen Discontinues Quest for New CETP Heart Drug

  Amgen inherited the drug after acquiring Dezima Pharma in a $1.2 billion deal in 2015.

  October 25, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Ablynx Banks $200M IPO in Nasdaq Debut

  Ablynx announced the price of its U.S. IPO at $17.50.

  October 25, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Why Even Spinraza Can’t Save Biogen’s Incoming MS Meltdown

  Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year.

  October 25, 2017

   · 

  4 min read

   · 

  Mark Terry
• 

  Biotech Bay

  Investors May be Overlooking This Small, Fast-Growing Bay Area Biotech

  You’ve probably heard those advertisements for “the power of protein,” referring to the addition of enzymes to detergent.

  October 25, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Bay Area’s Five Prime Promotes COO to CEO, Effective January 1, 2018

  After four months of looking, Five Prime Therapeutics has found its new CEO.

  October 25, 2017

   · 

  2 min read

   · 

  Alex Keown
• Pharm Country

  Creative BioMart Launched Protein Phosphorylation Site Identification and Mapping Service

  Creative BioMart announced the release of Protein Phosphorylation Site Identification and Mapping Service to serve a broader range of scientists.

  October 25, 2017

   · 

  1 min read
• Russian Biotechnology Company BIOCAD Prepares to Enters the European Market

  The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines.

  October 25, 2017

   · 

  3 min read
• BioForest

  Immune Design Prices $80M Public Offering of Common Stock

  All of the shares of common stock are being offered by Immune Design.

  October 25, 2017

   · 

  4 min read
• Business

  Epizyme Announces Date of Third Quarter 2017 Financial Results

  The webcast can be accessed under “Events and Presentations” in the Investor Relations section of the company’s website

  October 25, 2017

   · 

  1 min read
• Pharm Country

  Creative Biolabs Can Help Reduce Immunogenicity While Remaining the Affinity With Humanized Antibody Germinalization

  Creative Biolabs has successfully developed GHA platform to germinalize humanized antibody production.

  October 25, 2017

   · 

  2 min read